1. Gao, T.; Xu, J.; Xiao, Y.; Li, J.; Hu, W.; Su, X.; Shen, X.; Wan, Y.; Chen, Z.; Li, H.*; Wang, X.*, Therapeutic effects and mechanisms of N -(9,10anthraquinone-2-ylcarbonyl) xanthine oxidase inhibitors on hyperuricemia. Frontiers in pharmacology 2022. Accept (IF= 5.988)
2. Yue, S.; Xue, N.; Li, H.; Chen, Z.; Huang, B.*; Wang, X.*, Isomangiferin Attenuates Renal Injury in Diabetic Mice via Inhibiting Inflammation. Diabetes, metabolic syndrome and obesity : targets and therapy 2020, 13, 4273-4280; (IF=2.842)
3. Yue, S.; Xue, N.; Li, H.; Huang, B.; Chen, Z.; Wang, X.*, Hepatoprotective Effect of Apigenin Against Liver Injury via the Non-canonical NF-kappaB Pathway In Vivo and In Vitro. Inflammation 2020, 43 (5), 1634-1648. (IF=3.212)
4. Wang, X.; Zhang, D. M.; Gu, T. T.; Ding, X. Q.; Fan, C. Y.; Zhu, Q.; Shi, Y. W.; Hong, Y.; Kong, L. D., Morin reduces hepatic inflammation-associated lipid accumulation in high fructose-fed rats via inhibiting sphingosine kinase 1/sphingosine 1-phosphate signaling pathway. Biochemical pharmacology 2013, 86 (12), 1791-804. (IF=4.576)
5. Wang, X.; Lou, Y. J.; Wang, M. X.; Shi, Y. W.; Xu, H. X.; Kong, L. D., Furocoumarins affect hepatic cytochrome P450 and renal organic ion transporters in mice. Toxicology letters 2012, 209 (1), 67-77. (IF=3.145)
6. Wang, X.; Wang, C. P.; Hu, Q. H.; Lv, Y. Z.; Zhang, X.; Ouyang, Z.; Kong, L. D., The dual actions of Sanmiao wan as a hypouricemic agent: down-regulation of hepatic XOD and renal mURAT1 in hyperuricemic mice. Journal of ethnopharmacology 2010, 128 (1), 107-15. (IF=2.466)
(1) Pharmacology of metabolic diseases.
(2) Compound Chinese medicine and its monomer pharmacology.
(3) Inflammation
1. Research Projects
(1) Organization Department of Jurong Municipal Party Committee, Jiangsu Province, 2019 Jurong Blessed Land and Talents Plan Project, 201913, 2019-12-2024-12
(2) Jiangsu Provincial Department of Science and Technology, Basic Research Program (Natural Science Foundation) - Youth Fund Project, BK20180574, 2018-07 to 2021-06
(3) Nanjing Jiangning District Science and Technology Bureau, Jiangning District Science and Technology Development Project, 2018Ca12, 2018-01-2018-12
(4) Basic scientific research business fees of China Pharmaceutical University, Central University, 2016ZPY017, 2016-01-2017-12
(5) Research Special Fund of China Pharmaceutical University, China Pharmaceutical University, ZJ14109, 2014-01-2015-12
(6) National Natural Science Foundation of China, 82173887, 2022-01-2025-12, Participation
(7) National Natural Science Foundation of China, 31870325, 2019-01-2022-12, Participation
(8) National Natural Science Foundation of China, 81803457, 2019-01-2021-12, Participation
(9) National Natural Science Foundation of China, 81773745, 2018-01-2021-12, Participation
(10) National Natural Science Foundation of China, 81773826, 2018-01-2021-12, Participation
2. Representative Research Achievements
(1) N-9,10-anthraquinone-2-formylphenylalanine (NAY) can reduce uric acid from multiple perspectives and has renal protective effects. Current results indicate that NAY significantly inhibits XOD activity, while reducing serum uric acid, creatinine, and urea nitrogen levels, and regulating the expression of uric acid transporters GLUT9, OAT1, and OTA3. By blocking the activation of Caspase-1, inhibiting inflammatory reactions, and interfering with the NLRP3 inflammatory signal pathway. In addition, it has significant protective effects on liver and kidney damage in mice with hyperuricemia, while NAY has good efficacy and low toxicity, which has a good development prospect as a future anti-hyperuricemia drug.
(2) Morin may inhibit SphK1/S1P/S1PR1/3 axis mediated NF- κ Activation of B and inflammation improve liver insulin and leptin sensitivity in rats with fructose metabolic syndrome, thereby reducing hyperlipidemia and liver lipid accumulation, providing a new theoretical basis for the underlying pathogenesis of NAFLD caused by metabolic syndrome, and suggesting that morin may become a potential drug for preventing and treating NAFLD with metabolic syndrome.
1. Gao, T.; Xu, J.; Xiao, Y.; Li, J.; Hu, W.; Su, X.; Shen, X.; Wan, Y.; Chen, Z.; Li, H.*; Wang, X.*, Therapeutic effects and mechanisms of N -(9,10anthraquinone-2-ylcarbonyl) xanthine oxidase inhibitors on hyperuricemia. Frontiers in pharmacology 2022. Accept (IF= 5.988)
2. Yue, S.; Xue, N.; Li, H.; Chen, Z.; Huang, B.*; Wang, X.*, Isomangiferin Attenuates Renal Injury in Diabetic Mice via Inhibiting Inflammation. Diabetes, metabolic syndrome and obesity : targets and therapy 2020, 13, 4273-4280; (IF=2.842)
3. Yue, S.; Xue, N.; Li, H.; Huang, B.; Chen, Z.; Wang, X.*, Hepatoprotective Effect of Apigenin Against Liver Injury via the Non-canonical NF-kappaB Pathway In Vivo and In Vitro. Inflammation 2020, 43 (5), 1634-1648. (IF=3.212)
4. Wang, X.; Zhang, D. M.; Gu, T. T.; Ding, X. Q.; Fan, C. Y.; Zhu, Q.; Shi, Y. W.; Hong, Y.; Kong, L. D., Morin reduces hepatic inflammation-associated lipid accumulation in high fructose-fed rats via inhibiting sphingosine kinase 1/sphingosine 1-phosphate signaling pathway. Biochemical pharmacology 2013, 86 (12), 1791-804. (IF=4.576)
5. Wang, X.; Lou, Y. J.; Wang, M. X.; Shi, Y. W.; Xu, H. X.; Kong, L. D., Furocoumarins affect hepatic cytochrome P450 and renal organic ion transporters in mice. Toxicology letters 2012, 209 (1), 67-77. (IF=3.145)
6. Wang, X.; Wang, C. P.; Hu, Q. H.; Lv, Y. Z.; Zhang, X.; Ouyang, Z.; Kong, L. D., The dual actions of Sanmiao wan as a hypouricemic agent: down-regulation of hepatic XOD and renal mURAT1 in hyperuricemic mice. Journal of ethnopharmacology 2010, 128 (1), 107-15. (IF=2.466)
